(RTTNews) – Novavax Inc. (NVAX) announced Tuesday that it will begin a complex test of its COVID-19 vaccine in the United States and Mexico until the end of November. Previously, I was about to start this month. The company is also awaiting interim information from an ongoing Phase 3 trial of its COVID-19 vaccine in the first quarter of 2021.
In an update to its Phase 3 clinical progression program for its COVID-19 candidate vaccine, NVX-CoV2373, Novavax said it has made significant progress in large-scale manufacturing, with delays in original calendar estimates.
The company said its key Phase 3 test was conducted with the US government. As a component of Operation Warp Speed. The design of the test is aligned with those of other giant corporations and requires the registration of up to 30,000 participants in the United States and Mexico.
In addition, the company announced that it will provide knowledge of its ongoing Phase 1/2 clinical trial, adding new knowledge of Phase 2 reactogenicity on October 30 on the Immunization Practice Advisory Committee of the U. S. Centers for Disease Control and Prevention.
Meanwhile, Novavax said it expects interim knowledge of the ongoing Phase 3 trial of its UK coronavirus vaccine in the first quarter of 2021.
The company said it would expand the Phase 3 trial in the UK, which began in September in partnership with the UK government’s Vaccine Working Group, to 15,000 volunteers consisting of 10,000. within a period of time.
To date, Novavax has registered more than 5,500 participants in the UK and expects the test to be registered until the end of November.
NVX-CoV2373 is a candidate vaccine designed from the SARS-CoV-2 genetic series, the virus guilty of COVID-19 disease. NVX-CoV2373 was created using Novavax’s recombinant nanoparticle generation to generate an antigen derived from complex coronavirus protein (S Includes Novavax’s patented saponin-based Matrix-M adjuvant for immune reaction and seasoning the upper grades of neutralizing antibodies.